Endocyte, Inc. (ECYT) Secures DOXIL® Supply to Support Ongoing Phase 3 PROCEED Trial in Ovarian Cancer
8/2/2012 9:54:58 AM
WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL® (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer. The PROCEED trial compares vintafolide in combination with DOXIL versus DOXIL alone for the treatment of folate-receptor positive platinum resistant ovarian cancer.
comments powered by